Metastasis in colorectal cancer: What makes the tumor aggressive?

European Journal of Surgery, Supplement

Volumn 164, Issue 582, 1998, Pages 104-110

  Hecht, Joel Randolph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion molecules; Angiogenesis; Colorectal cancer; Metastasis

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL ADHESION MOLECULE; FUMAGILLOL CHLOROACETYLCARBAMATE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER INVASION; COLORECTAL CANCER; HUMAN; METASTASIS; PRIORITY JOURNAL; TUMOR EMBOLISM; CELL DIVISION; COLORECTAL TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CELL ADHESION MOLECULES; CELL DIVISION; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032216801     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. 1. Agrez MV. Cell adhesion molecules and colon cancer. Aust N Z J Surg 1996; 66: 791-798.
2. 2. al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 1993; 71: 1954-1959.
3. 3. An Z, Wang X, Willmott N, et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metast 1997; 15: 184-195.
4. 4. Belluco C, Guillem JG, Kemeny N, et al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996; 14: 2696-2701.
5. 5. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-334.
6. 6. Bresalier RS. The biology of colorectal cancer metastasis. Gastroenterol Clin North Am 1996; 25: 805-820.
7. 7. Bresalier RS, Ho SB, Schoeppner HL, et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterol 1996; 110: 1354-1367.
8. 8. Bresalier RS, Hujanen ES, Raper SE, et al. An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res 1987; 47: 1398-1406.
9. 9. Bresalier RS, Niv Y, Byrd JC, et al. Mucin production by human colonie carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991; 87: 1037-1045.
10. 10. Cho KR, Fearon ER. DCC: linking tumour suppressor genes and altered cell surface interactions in cancer? Eur J Cancer 1995; 31A: 1055-1060.
11. 11. Choi HJ, Jung IK, Kim SS, Hong SH. Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas. Dis Col Rectum 1997; 40: 51-59.
12. 12. Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and pratice of oncology. Philadelphia, PA: Lippincott-Raven Publishers, 1997: 1144.
13. 13. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 1993; 142: 981-986.
14. 14. el-Deity WS, Harper JW, O'Connor PM, et al. WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
15. 15. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-56.
16. 16. Flamini G, Curigliano G, Ratto C, et al. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 1996; 32A: 802-806.
17. 17. Folkman J, Long D, Becker F. Growth and metastasis of tumors in organ culture. Cancer 1963; 16: 453-647.
18. 18. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995; 222: 695-699.
19. 19. Ganesh S, Sier CF, Heerding MM, et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997; 75: 1793-1801.
20. 20. Giavazzi R, Foppolo M, Dossi R, et al. Rolling and adhesion of human tumor cells on vascular epithelium under physiologic conditions. J Clin Invest 1993; 92: 3038-3044.
21. 21. Gradishar WJ. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs. 1997; 15: 49-59.
22. 22. Griffini P, Smorenburg SM, Verbeek FJ, van Noorden CJ. Three-dimensional reconstruction of colon carcinoma metastases in liver. J Microsc 1997; 187: 12-21.
23. 23. Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg 1995; 19: 226-234.
24. 24. Hedrick L, Cho KR, Fearon ER, Wu TC, Kinzler KW, Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994; 8: 1174-1183.
25. 25. Herrlich P, Pals S, Ponta H. CD44 in colon cancer. Eur J Cancer 1995; 31A: 1110-1112.
26. 26. Hostetter RB, Augustus LB, Mankarious R, et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990; 82: 380-385.
27. 27. Indinnimeo M, Giarnieri E, Stazi A, et al. Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression. Cancer Lett 1997; 111: 1-5.
28. 28. Itoh F, Yamamoto H, Hinoda Y, Imai K. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells. Cancer 1996; 77: 1717-1721.
29. 29. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221.
30. 30. Jou TS, Stewart DB, Stappert J, Nelson WJ, Marrs JA. Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex. Proc Natl Acad Sci U S A 1995; 92: 5067-5071.
31. 31. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-1113.
32. 32. Kinsella AR, Lepts GC, Hill CL, Jones M. Reduced E-cadherin expression correlates with increased invasiveness in colorectal carcinoma cell lines. Clin Exp Metast 1994; 12: 335-342.
33. 33. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661-665.
34. 34. Kitadai Y, Ellis LM, Tucker SL, et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996; 149: 1541-1551.
35. 35. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994; 1221: 211-214.
36. 36. Lane DP. A death in the life of p53. Nature 1993; 362: 786-787.
37. 37. Lanza Jr G, Maestri I, Dubini A, et al. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol 1996; 105: 604-612.
38. 38. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996; 180: 364-370.
39. 39. Levy AT, Cioce V, Sobel ME, et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439-444.
40. 40. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-326.
41. 41. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
42. 42. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med 1996; 2: 461-462.
43. x antigen correlates with poor survival in patients with colorectal carcinoma: clinico-pathological and immunohistochemical study. Cancer Res 1993; 53: 3632-3637.
44. 44. Nakamura T, Tabuchi Y, Nakae S, Ohno M, Saitoh Y. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival. Cancer 1996; 77: 1741-1746.
45. 45. Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Col Rectum 1994; 37: 527-534.
46. 46. Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 1997; 15: 29-37.
47. 47. Nguyen M, Strubel NA, Bischoff J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 1993; 365: 267-269.
48. 48. Nicolson GL. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993; 204: 171-180.
49. 49. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
50. 50. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237.
51. 51. Price JT, Bonovich MT, Kohn EC. The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 1997; 32: 175-253.
52. 52. Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995; 14: 323-338.
53. 53. Radinsky R, Bucana CD, Ellis LM, et al. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res 1993; 53: 937-943.
54. 54. Rasmussen H, Rugg T, Brown P, Baillet M, Millar A. A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. (Abstract) Proceedings of ASCO. 1997; 16: 429a.
55. 55. Remvikos Y, Tominaga O, Hammel P, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992; 66: 758-764.
56. 56. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Col Rectum 1994; 37: 921-926.
57. 57. Schwartz MK. Tissue cathepsins as tumor markers. Clin Chim Acta 1995; 237: 67-78.
58. 58. Senda T, Miyashiro I, Matsumine A, et al. The tumor suppressor protein APC colocalizes with beta-catenin in the colon epithelial cells. Biochem Biophys Res Commun 1996; 223: 329-334.
59. 59. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335: 1727-1732.
60. 60. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
61. 61. Slebos RJ, Baas IO, Clement M, et al. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996; 74: 165-171.
62. 62. Stallmach A, von Lampe B, Matthes H, Bornhoft G, Riecken EO. Diminished expression of integrin adhesion molecules on human colonie epithelial cells during the benign to malign tumour transformation. Gut 1992; 33: 342-346.
63. 63. Starzynska T, Bromley M, Ghosh A, Stern PL, Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-562.
64. 64. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200-204.
65. 65. Streit M, Schmidt R, Hilgenfeld RU, Thiel E, Kreuser ED. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med 1996; 74: 253-268.
66. 66. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993; 262: 1734-1737.
67. 67. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B. Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 1996; 32A: 1963-1967.
68. 68. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132: 541-546.
69. 69. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-231.
70. 70. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995; 55: 836-839.
71. 71. Trowbridge IS, Lesley J, Schulte R, Hyman R, Trotter J. Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues. Immunogenetics 1982; 15: 299-312.
72. 72. Vermeulen SJ, Bruyneel EA, Bracke ME, et al. Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res 1995; 55: 4722-4728.
73. 73. Verspaget HW, Sier CF, Ganesh S, Griffloen G, Lamers CB. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 1995; 31A: 1105-1109.
74. 74. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal tumors. Science 1989; 244: 207-211.
75. 75. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
76. 76. von Lampe B, Stallmach A, Riecken EO. Altered glycosylation of integrin adhesion molecules in colorectal cancer cells and decreased adhesion to the extracellular matrix. Gut 1993; 34: 829-836.
77. 77. Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 1997; 123: 118-123.
78. 78. Wang L, Patel U, Ghosh L, Chen HC, Banerjee S. Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer Res 1993; 53: 717-720.
79. 79. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-1797.
80. 80. Wielenga VJ, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-4756.
81. 81. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.
82. 82. Yamaguchi A, Urano T, Fushida S, et al. Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. Br J Cancer 1993; 68: 1020-1024.
83. 83. Yamaguchi A, Urano T, Goi T, et al. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996; 14: 1122-1127.
84. 84. Yang JL, Ow KT, Russell PJ, Ham JM, Crowe PJ. Higher expression of oncoproteins c-myc, c-erb B-2/ neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Ann Surg Oncol 1996; 3: 574-579.
85. 85. Ye C, Kiriyama K, Mistuoka C, et al. Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer 1995; 61: 455-460.
86. 86. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133-3140.